Catalog No.
Product Name
Application
Product Information
Citations
-
Nrf2 Activator
Eriodictyol-7-O-glucoside is a flavonoid that functions as an Nrf2 activator. It demonstrates potent scavenging activity against hydroxyl radicals and superoxide anions, with IC50 values of 0.28 mM and 0.30 mM, respectively. This compound enhances the nuclear localization of Nrf2, leading to the induction of Nrf2/ARE-dependent gene expression. Eriodictyol-7-O-glucoside offers protective effects against oxidative stress induced by oxygen and glucose deprivation, and exhibits neuroprotective properties in models of focal cerebral ischemia. It is valuable for research in stroke and neuroprotection studies. -
NRF2 Activator
Monoethyl fumarate is the monoethyl ester of fumaric acid and serves as an activator of the Nrf2 pathway. This compound exhibits significant potential for antioxidant activity and may play a crucial role in cellular defense mechanisms. Its applications extend to research involving neuroprotection and inflammation modulation, as well as in the exploration of therapeutic strategies for various diseases. Additionally, monoethyl fumarate is utilized as a preservative and polymerization agent for macromolecular materials. -
Keap1-Nrf2 PPI Inhibitor
NXPZ-2 is an orally active inhibitor of the Keap1-Nrf2 protein-protein interaction with a Ki value of 95 nM and EC50 values of 120 and 170 nM. It has demonstrated the ability to dose-dependently mitigate Aβ[1-42]-induced cognitive dysfunction and improve brain tissue pathology in Alzheimer's disease models by enhancing neuronal quantity and function. NXPZ-2 functions by inhibiting oxidative stress through increased expression of Nrf2 and promoting its translocation from the cytoplasm to the nucleus, supporting research into Keap1-Nrf2 interactions and Alzheimer’s disease. -
Anticancer/Anti-inflammatory Agent
Antroquinonol, a ubiquinone derivative derived from the mushroom Antrodia camphorata, demonstrates notable anticancer and anti-inflammatory properties. This compound is primarily studied for its potential in colon cancer research due to its ability to reduce oxidative stress by activating the Nrf2 signaling pathway. Additionally, Antroquinonol has shown efficacy in inhibiting inflammation and sclerosis in models of focal segmental glomerulosclerosis. -
Nrf2 Activator
Nrf2 activator-3 is a potent activator of the NF-E2-related factor 2 (Nrf2) pathway. This compound enhances antioxidant response element (ARE) transcriptional activity, promoting the expression of various cytoprotective genes. Nrf2 activator-3 is primarily utilized in research focusing on cerebral ischemic injury, where it may help elucidate mechanisms of neuroprotection and potential therapeutic strategies. -
NRF2 Activator
CBR-470-2 is a glycine-substituted analog that functions as an NRF2 activator. This compound significantly enhances NRF2 signaling pathways, making it a valuable tool for research into metabolic modulation, particularly glycolysis. Its ability to influence key cellular processes positions CBR-470-2 as an important reagent for exploring the roles of oxidative stress and inflammation in various biological systems. -
Keap1-Nrf2 PPI Inhibitor
Keap1-Nrf2-IN-13 is a potent inhibitor of the Keap1-Nrf2 protein-protein interaction (PPI), exhibiting an IC50 of 0.15 μM. This compound effectively disrupts the binding of Keap1 to Nrf2 by establishing hydrogen bonds with critical polar residues such as Asn414, Arg415, Arg483, and Gln530. Keap1-Nrf2-IN-13 is valuable for research focused on oxidative stress-related conditions and inflammatory diseases, including pulmonary fibrosis, chronic obstructive pulmonary disease (COPD), and various cancers. -
Keap1-Nrf2 Inhibitor
Toralactone is a selective inhibitor of the Keap1-Nrf2 pathway, which plays a crucial role in cellular antioxidant defense mechanisms. Originating from Cassia obtusifolia, Toralactone exhibits significant hepatoprotective effects mediated through Nrf2 activation. This compound is suitable for research applications focused on oxidative stress, hepatotoxicity, and the modulation of antioxidant responses in various biological systems. -
Keap1-Nrf2 Inhibitor
Nrf2 activator-12 is a potent activator of the Keap1-Nrf2 pathway, with an EC50 value of 83.5 nM. This compound demonstrates significant pharmacological effects, including the ability to reverse disease progression and mitigate demyelination in an experimental autoimmune encephalomyelitis mouse model. Nrf2 activator-12 is valuable for studies exploring oxidative stress responses and potential neuroprotective strategies in various neurological disorders. -
Keap1-Nrf2 PPI Inhibitor
Keap1-Nrf2-IN-9 is a selective inhibitor of the Keap1-Nrf2 protein-protein interaction (PPI) with a reported IC50 of 0.575 μM. This compound enhances the expression of Nrf2 target genes, including heme oxygenase 1 (Hmox1), glutathione S-transferase P (GstP), and the modulatory and catalytic subunits of glutamate-cysteine ligase (Gclc and Gclm). Keap1-Nrf2-IN-9 exhibits low cytotoxicity in ARPE19 cells, making it a valuable tool for studies focused on oxidative stress and cellular defense mechanisms. -
Nrf2 Activator
Nrf2 activator-1 is a potent activator of the NF-E2 related factor 2 (Nrf2), a key regulator of cellular antioxidant response. It demonstrates significant biological activity in modulating oxidative stress and inflammation. This compound is valuable for research applications related to chronic obstructive pulmonary disease (COPD), asthma, acute lung injury (ALI), acute respiratory distress syndrome (ARDS), and pulmonary fibrosis, facilitating the exploration of therapeutic interventions in these conditions. -
NRF2 Activator
MIND4-17 is a selective NRF2 activator that covalently modifies the C151 residue of Keap1. By disrupting the association between Keap1 and Nrf2, MIND4-17 promotes Nrf2 protein stabilization and subsequent nuclear translocation, enhancing the cellular antioxidant response. This compound demonstrates strong antioxidant activity and is valuable for research applications focused on oxidative stress and related pathways. -
Keap1-Cul3 E3 ligase Complex Allosteric Molecular Glues
VVD 065 is an allosteric modulator of the Keap1-Cul3 E3 ligase complex that functions as a molecular glue. By activating KEAP1, VVD 065 promotes the degradation of NRF2, an essential regulator of antioxidant defenses. This compound has demonstrated the ability to inhibit tumor growth in non-small cell lung cancer and esophageal squamous cell carcinoma xenograft models. VVD 065 serves as a valuable tool for research on cancer biology and therapeutic strategies targeting oxidative stress responses. -
NR0B1-protein Interactions Destructive Agent
BPK-29 hydrochloride is a selective agent that disrupts interactions between the atypical orphan nuclear receptor NR0B1 and its protein partners, such as RBM45 and SNW1, through covalent modification of cysteine residue C274. This compound has been shown to inhibit anchorage-independent growth in KEAP1-mutant cancer cell lines, making it a valuable tool for studying the biological functions of NR0B1 and its role in cancer development. BPK-29 hydrochloride is essential for research on targeted therapies in oncology and the mechanisms underlying cancer cell proliferation. -
Keap1-Nrf2 PPI Inhibitor
Keap1-Nrf2-IN-7 is a potent inhibitor of the Keap1-Nrf2 protein-protein interaction (PPI), exhibiting an IC50 value of 0.45 µM. This compound plays a crucial role in modulating the Nrf2 signaling pathway, which is essential for cellular responses to oxidative stress. Its application is significant in studies focused on neuroprotection, cancer therapy, and various diseases associated with oxidative damage. -
Endogenous Metabolite
9(R)-HODE is a monohydroxy fatty acid and an endogenous metabolite of linoleic acid, generated through the enzymatic actions of cyclooxygenase (COX) and lipoxygenase (LO). This compound is known to promote chemotaxis and elevate the expression of chemokine receptors CCR9 and CXCR4 in immune cells. Additionally, 9(R)-HODE effectively inhibits interleukin-6 (IL-6) release in primary human monocytes and suppresses CD3α- and CD28-induced proliferation in isolated human peripheral blood lymphocytes at a concentration of 25 μg/mL, making it a valuable tool for studying immune responses and inflammatory processes. -
Anti-Inflammatory Agent
3-Aminoisobutyric acid sodium salt acts as an anti-inflammatory agent through its antioxidant properties. It enhances the expression of brown adipocyte-specific genes within white adipose tissue and promotes fatty acid β-oxidation in hepatocytes. This compound has been shown to mitigate insulin resistance and inflammation triggered by palmitate or high-fat diets via an AMPK–PPARδ-dependent pathway in murine models. Additionally, 3-Aminoisobutyric acid sodium salt is a catabolic metabolite of thymine and valine in skeletal muscle. -
Immunomodulatory/Antineoplastic Agent
Lenalidomide hydrochloride is an oral immunomodulatory agent targeting cereblon (CRBN), acting as a molecular glue. It promotes the selective ubiquitination and degradation of transcription factors IKZF1 and IKZF3 via the CRBN-CRL4 ubiquitin ligase complex. This mechanism effectively inhibits the growth of mature B-cell lymphomas, including multiple myeloma, while also inducing the release of IL-2 from T cells, making it valuable in cancer research and therapeutic applications. -
DCAF1 Ligand
MY-11B is a ligand for DCAF1, specifically exhibiting reactivity with the DCAF1_C1113 domain. This compound effectively inhibits YT41R and YT47R-mediated degradation of HA-FKBP12, making it a valuable tool in studying protein degradation pathways. MY-11B is also applicable in the synthesis of PROTACs, contributing to the development of targeted protein degradation strategies in chemical research. -
FAP-PI3K Inhibitor
FAP-PI3KI1 is a fibroblast-activated protein (FAP) inhibitor that selectively targets the phosphoinositide 3-kinase (PI3K) pathway in FAP-expressing human cells. This compound effectively inhibits collagen synthesis and reduces collagen deposition, making it a valuable tool for research in idiopathic pulmonary fibrosis (IPF) and related fibrotic conditions. Its targeted action facilitates investigating the role of the PI3K signaling pathway in fibrosis and offers potential insights into therapeutic strategies for IPF. -
Antibacterial Agent
Cloxacillin is an orally active antibacterial agent and β-lactamase inhibitor, exhibiting an IC50 of 0.04 µM. It effectively suppresses the inflammatory response induced by Staphylococcus aureus by inhibiting the activation of mitogen-activated protein kinases (MAPKs), nuclear factor kappa B (NF-κB), and proteins associated with the NLRP3 inflammasome. This compound is useful for research applications focused on bacterial infections and inflammatory processes. -
COX1/2 Inhibitor
Indomethacin sodium is a potent inhibitor of cyclooxygenase enzymes COX-1 and COX-2, exhibiting IC50 values of 18 nM and 26 nM, respectively. This compound demonstrates significant anticancer and anti-infective properties, making it valuable in various biological research applications. Indomethacin sodium is essential for investigating mechanisms related to cancer treatment, inflammation, and viral infections. -
Nrf2 Activator
Ginnalin A, a potent Nrf2 activator, demonstrates significant antiproliferative activity against HCT116, SW480, and SW620 cancer cell lines, with IC50 values of 24.8, 22.0, and 39.7 μM, respectively. This compound induces S phase arrest in cancer cells and activates the p62-Keap1-Nrf2 signaling pathway, leading to the upregulation of mRNA and protein expressions of key protective markers such as Nrf2, HO-1, and NQO1. Additionally, Ginnalin A promotes the translocation of Nrf2 from the cytoplasm to the nucleus, making it a valuable tool for research into colon cancer mechanisms and potential therapies. -
Keap1/S349-p-p62 Interaction Inhibitor
K67 is a selective inhibitor targeting the interaction between Keap1 and S349 phosphorylated p62, with an IC50 of 1.5 μM. This compound demonstrates a weaker inhibitory effect on the Keap1-Nrf2 interaction (IC50 of 6.2 μM) and functions by competitively binding to Keap1's binding site, disrupting the aberrant activation of the p62-dependent Nrf2 pathway. K67 has been shown to inhibit tumor cell proliferation and increase the sensitivity of hepatocellular carcinoma (HCC) cells to chemotherapeutic agents by restoring Keap1-mediated ubiquitination and subsequent degradation of Nrf2. This makes K67 a valuable tool for investigating therapeutic strategies in cancer research. -
Anti-Inflammatory Agent
Triptohypol C is a Tripterin derivative that functions as a potent anti-inflammatory agent by specifically targeting Nur77. It exhibits a Kd value of 0.87 μM, facilitating the modulation of inflammatory responses through enhanced interactions between Nur77 and TRAF2 as well as p62/SQSTM1. This compound is valuable for research applications focusing on inflammation and related signaling pathways. -
AUTAC Ligand
TSPO ligand-3 serves as a ligand for AUTAC2, which features a p-fluorobenzylguanine (FBnG) moiety alongside a synthetic FKBP ligand (SLF). This compound exhibits notable biological activity by significantly silencing FKBP12 in HeLa cells. Research applications include studying targeted protein degradation and investigating the mechanistic pathways of autophagy-related and intracellular degradation processes. -
iNOS/ PKC-θ Dual Inhibitor
(Rac)-Anemonin is a dual inhibitor targeting inducible nitric oxide synthase (iNOS) and protein kinase C theta (PKC-θ). It selectively inhibits iNOS while also reducing the stability of the PKC-θ protein, showcasing significant biological activity. Research indicates that (Rac)-Anemonin can alleviate symptoms in dextran sodium sulfate-induced acute ulcerative colitis in murine models, making it valuable for studying inflammation-related diseases. -
iNOS/ PKC-θ Dual Inhibitor
Anemonin is a dual inhibitor targeting inducible nitric oxide synthase (iNOS) and protein kinase C theta (PKC-θ). This compound significantly reduces the translation and enhances the protein stability of PKC-θ, demonstrating potent anti-inflammatory effects. Anemonin has been shown to alleviate symptoms of dextran sodium sulfate-induced acute ulcerative colitis in murine models, making it a valuable tool for researching inflammation-related diseases. -
PAD4 Inhibitor
GSK484 is a selective inhibitor of peptidylarginine deiminase 4 (PAD4), effectively blocking the enzyme's catalytic activity to inhibit protein citrullination and neutrophil extracellular trap (NET) formation. This compound demonstrates anti-inflammatory properties by reducing histone H3 production, modulating MHC-I expression, and inhibiting CD8+ T cell activation and proliferation. Research applications include studies on rheumatoid arthritis, sickle cell disease, myocardial ischemia-reperfusion injury, and colitis, as well as investigations into intestinal microbial homeostasis and ferroptosis-related dysbiosis. -
PAD4 Inhibitor
JBI-589 is a non-covalent inhibitor selectively targeting the PAD4 isoform. This compound effectively reduces CXCR2 expression and inhibits neutrophil chemotaxis, making it instrumental in the study of inflammatory processes. JBI-589 demonstrates potential in diminishing primary tumors and metastases while enhancing the efficacy of checkpoint inhibitors. It is suitable for various applications in cancer research. -
HLA-A*0201 Stabilizer
ELTLGEFLKL is a survivin-derived peptide that functions as a stabilizer of HLA-A*0201. This peptide demonstrates significant enhancement of HLA-A*0201 stability, making it a valuable tool in the study of tumor immunotherapy. ELTLGEFLKL can be employed in research focused on optimizing immune responses against cancer through modulation of peptide-MHC interactions. -
CCR3 Antagonist
SB-328437 is a selective non-peptide antagonist of the CCR3 receptor, demonstrating an IC50 of 4.5 nM. This compound effectively inhibits eosinophil migration induced by eotaxin, eotaxin-2, and monocyte chemotactic protein-4, making it valuable in studies of allergic inflammation. Additionally, SB-328437 has shown the ability to sensitize 5-FU-resistant gastric cancer cells and reduce neutrophil recruitment to the lungs, thus mitigating pulmonary inflammation during acute inflammatory responses. Its applications extend to the investigation of various inflammation-related diseases. -
Anti-inflammatory and Analgesic Agent
Deoxyartemisinin (2-Deoxyartemisinin) is an orally active anti-inflammatory and analgesic agent that selectively reduces the pro-inflammatory cytokine TNF-α. This compound demonstrates efficacy in alleviating various forms of pain, including neuropathic and inflammatory pain, as well as reducing croton oil-induced ear edema. Additionally, Deoxyartemisinin exhibits anti-ulcer properties, making it a valuable tool for research focused on inflammatory diseases, pain management, and gastric ulcers. -
TNFSF13B/BAFF/CD257 Inhibitor
Aritinercept is a recombinant fusion protein that functions as an inhibitor of TNFSF13B (BAFF/CD257). This compound effectively neutralizes BAFF and APRIL, leading to reduced B cell proliferation and suppression of peripheral B cells, along with a decrease in serum immunoglobulins. Aritinercept has demonstrated beneficial effects in a mouse model of systemic lupus erythematosus (SLE) by lowering markers of renal damage, as well as reducing levels of IFNγ, IL-17A, and anti-dsDNA autoantibodies. This reagent is suitable for research focused on systemic lupus erythematosus and related autoimmune disorders. -
CXCR6 Antagonist
ML339 is a selective antagonist of the CXCR6 receptor, displaying an IC50 of 140 nM. It inhibits β-arrestin recruitment and the cAMP signaling pathway induced by CXCL16 in human CXCR6, with IC50 values of 0.3 μM and 1.4 μM, respectively. While exhibiting reduced efficacy against mouse CXCR6 with an IC50 of 18 μM, ML339 demonstrates no significant inhibition of CXCR5, CXCR4, or the apelin receptor (APJ), with IC50 values exceeding 79 μM. This compound shows promise for advancing research focused on prostate cancer. -
CXCR Inhibitor
ALX 40-4C is a small peptide inhibitor targeting the chemokine receptor CXCR4. It effectively prevents the binding of SDF-1 to CXCR4 with a Ki of 1 μM, thereby inhibiting the replication of X4 strains of HIV-1. Additionally, ALX 40-4C Trifluoroacetate serves as an antagonist of the APJ receptor, exhibiting an IC50 value of 2.9 μM. This dual activity makes ALX 40-4C a valuable tool for research in HIV-1 studies and chemokine receptor signaling pathways. -
CCR6 Antagonist
IDOR-1117-2520 is a potent and selective reversible antagonist targeting CCR6. It effectively inhibits CCL20-mediated calcium influx with an IC50 of 63 nM and blocks β-arrestin recruitment to human CCR6, showing an IC50 of 30 nM in recombinant cell models. As a substrate of P-glycoprotein/MDR1, IDOR-1117-2520 is a valuable tool for investigating autoimmune diseases and skin inflammation in research settings. -
CXCR Receptor Inhibitor
SCH-900875 is a selective inhibitor of the CXCR3 receptor, known for its oral bioavailability and ability to penetrate the blood-brain barrier. By binding to CXCR3, it effectively prevents the interaction of ligands CXCL9, CXCL10, and CXCL11, thereby inhibiting downstream G protein and β-arrestin signaling pathways, which reduces inflammatory cell migration. This compound holds potential for investigating various autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, as well as inflammatory conditions like psoriasis and inflammatory bowel disease. -
Anti-inflammatory agent
Emorfazone is a non-steroidal anti-inflammatory drug that functions primarily through the inhibition of bradykinin-like substances and kininogen release. This compound exhibits notable anti-inflammatory and analgesic properties, making it a valuable tool for research on pain management and inflammatory conditions. Its oral activity further expands its application in pharmacological studies aimed at understanding inflammatory pathways. -
Non-steroidal Anti-inflammatory Agent
Zoliprofen is a non-steroidal anti-inflammatory agent that primarily acts by antagonizing bradykinin, leading to significant suppression of bradykinin-induced edema and pain responses. It also exhibits a moderate inhibitory effect on arachidonic acid-induced edema and pain, while additionally inhibiting PGE2 synthesis in bovine vesicular gland microsomes. This dual action makes Zoliprofen a valuable tool for research applications focused on pain management and inflammatory processes. -
CETP Inhibitor/CB1 Agonist
BI-5756 is a selective CETP inhibitor and cannabinoid receptor 1 (CB1) agonist. It promotes a significant increase in HDL-C levels while reducing LDL-C levels, thereby improving lipid profiles. Additionally, BI-5756 enhances the function of regulatory T cells and preserves T cell-mediated anti-tumor activity, exhibiting direct anti-proliferative effects on tumor cells. This compound also upregulates the expression of MHC I, MHC II, and CD80 on tumor cells and demonstrates protective effects in graft-versus-host disease. BI-5756 is applicable in research related to oncology, graft-versus-host disease, and metabolic disorders. -
CB1R/iNOS Antagonist
(Rac)-Zevaquenabant is a potent cannabinoid receptor type 1 (CB1R) and iNOS antagonist, exhibiting a Ki value of 5.7 nM for CB1R. This compound is primarily utilized in studies related to liver fibrosis, providing valuable insights into its pathophysiology and potential therapeutic interventions. Its selective inhibition of CB1R and iNOS pathways makes it a significant tool for investigating cannabinoid signaling and its implications in fibrotic diseases. -
CXCR7 Antagonist
CXCR7 antagonist-1 functions as a CXCR7 antagonist by inhibiting the binding of the SDF-1 (CXCL12) and I-TAC (CXCL11) chemokines to the CXCR7 receptor. This inhibition plays a critical role in suppressing tumor cell proliferation and tumor growth, thereby providing potential therapeutic applications in cancer treatment. Additionally, CXCR7 antagonist-1 may be beneficial in the study and management of various inflammatory diseases and other pathologies associated with the CXCR7 pathway. -
Anti-inflammatory Agent
1-Terpineol is a lipid-soluble monoterpenoid alcohol recognized for its anti-inflammatory properties. This compound exhibits significant antibacterial and antioxidant activities, making it valuable for various research applications. It is commonly explored in studies related to inflammation and oxidative stress management. -
Antimicrobial and Anti-inflammatory Agent
1-Hydroxy-2-methylanthraquinone targets various biological pathways as an antimicrobial and anti-inflammatory agent. This compound demonstrates significant antimicrobial and antioxidant properties, making it useful for studies related to infection control and inflammation modulation. Its pesticidal activity further broadens its applicability in agricultural research and product development. -
Anti-inflammatory Agent
Anti-inflammatory agent 14, also known as compound 28, is a potent anti-inflammatory compound that inhibits inflammation-related pathways. It exhibits a minimum inhibitory concentration (MIC50) of 2 μM against Mycobacterium tuberculosis strain H37Rv, demonstrating significant antibacterial properties. This reagent is valuable for research applications focused on anti-inflammatory therapies and tuberculosis studies. -
Anti-inflammatory Agent
2-Methyldecalin is a chemical compound known for its anti-inflammatory properties. It exhibits significant antioxidant and antibacterial activities, making it a valuable reagent for studies related to inflammatory conditions. This compound is suitable for various research applications aimed at understanding and mitigating inflammation-related disorders. -
CcrM Inhibitor
NSC177365 is a potent CcrM inhibitor that acts by competitively disrupting DNA binding. It demonstrates significant antibacterial activity, displaying IC50 values of 2.3 μM and 14.6 μM against C. crescentus and M. lincolnii, respectively. Furthermore, NSC177365 has potential applications in reversing neurodegenerative disorders and shows promise as an anticancer agent, making it a valuable tool for chemical research. -
Anti-inflammatory Agent
Vasicinolone is a natural alkaloid that functions primarily as an anti-inflammatory agent. It demonstrates significant anti-inflammatory and antimicrobial activity, making it valuable for research applications related to inflammation and infection. Its potential use in therapeutic development highlights its importance in the study of chronic inflammatory conditions. -
Anti-inflammatory Agent
Anti-inflammatory agent 94 (compound 4b) is a potent cannabinoid ligand targeting the CB1 and CB2 receptors, exhibiting Kis of 29 nM and 8 nM, respectively. This compound demonstrates significant anti-inflammatory activity, making it a valuable tool for studying inflammation-related processes. Its application in research may enhance understanding of cannabinoid signaling and its therapeutic potential in inflammatory conditions.
